Business Update

ComGenex transfers to Echelon jointly developed IP for cancer compounds

Published in Gene Therapy Weekly, March 3rd, 2005

ComGenex announced it finalized an agreement with Echelon Biosciences, Inc., a subsidiary of Aterna Zentaris (AEZS), to transfer all rights to develop, manufacture, and market certain PI3K inhibitors that were created under their joint drug-discovery program.

As part of the transduction-signaling technology, these novel compounds could lead to new highly effective treatments for some forms of cancer.

Financial details were not disclosed.

Dr. Laszlo Urge, CEO of ComGenex, Inc., commented, "As Echelon is aggressively pursuing these drug-discovery and -development programs in the field of oncology, we think we made the best choice....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-03-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry